Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
B-RAF protein kinase inhibitor PLX 4032, 5 mg  

B-RAF protein kinase inhibitor PLX 4032, 5 mg

N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide

Synonyms: RG 7204; Vemurafenib; RO 5185426
PLX 4032 is a selective inhibitor of protein kinase, targeting B-Raf (V600E)

More details

PKI-PLX4032-005

Availability: within 3 days

117,00 €

Background: PLX 4032 / Vemurafenib is a selective inhibitor of protein kinase, targeting B-Raf (V600E) (IC50: 44 nM) as well as C-RAF and wildtype B-RAF; PLX4032 has been shown to cause programmed cell death in melanoma cell lines; a potential anti-tumor agent under clinical trials.

Chemical formula: C23H18ClF2N3O3S
Molecular weight: 489.92 g/mol
Purity: >99%
Appearance: White solid
Solubility: Soluble in DMSO
CAS Number: 918504-65-1

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers. 

References

G Bollag et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467, 596–599.
PI Poulikakos et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464, 427-430.
E Sala et al. BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells. Mol. Cancer Res. 2008, 6(5), 751-759.